Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Supernus Pharmaceuticals Inc’s stock clocked out at $49.26, down -0.28% from its previous closing price of $49.4. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 0.65 million shares were traded. SUPN stock price reached its highest trading level at $49.535 during the session, while it also had its lowest trading level at $47.8.
Ratios:
To gain a deeper understanding of SUPN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.92. For the most recent quarter (mrq), Quick Ratio is recorded 1.56 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On July 30, 2025, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $42.
Cantor Fitzgerald Downgraded its Overweight to Neutral on February 19, 2025, whereas the target price for the stock was revised from $57 to $36.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 19 ’25 when Mottola Frank sold 20,000 shares for $50.41 per share. The transaction valued at 1,008,150 led to the insider holds 15,496 shares of the business.
FRANK MOTTOLA bought 20,000 shares of SUPN for $985,600 on Dec 19 ’25. On Dec 18 ’25, another insider, Bhatt Padmanabh P., who serves as the Sr. VP of IP, CSO of the company, sold 710 shares for $44.44 each. As a result, the insider received 31,552 and left with 14,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2824536320 and an Enterprise Value of 2585588480. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.14 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 3.794 whereas that against EBITDA is 21.738.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.71, which has changed by 0.29795063 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $57.65, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is 1.74%, while the 200-Day Moving Average is calculated to be 22.36%.
Shares Statistics:
It appears that SUPN traded 819.82K shares on average per day over the past three months and 593170 shares per day over the past ten days. A total of 57.12M shares are outstanding, with a floating share count of 54.43M. Insiders hold about 5.07% of the company’s shares, while institutions hold 101.42% stake in the company. Shares short for SUPN as of 1765756800 were 4812734 with a Short Ratio of 5.87, compared to 1763078400 on 5202679. Therefore, it implies a Short% of Shares Outstanding of 4812734 and a Short% of Float of 11.85.
Earnings Estimates
. The current market rating for Supernus Pharmaceuticals Inc (SUPN) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.44, with high estimates of $0.47 and low estimates of $0.42.
Analysts are recommending an EPS of between $5.95 and $2.64 for the fiscal current year, implying an average EPS of $3.81. EPS for the following year is $4.25, with 3.0 analysts recommending between $6.04 and $3.25.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $195.64M. It ranges from a high estimate of $202.7M to a low estimate of $184.8M. As of. The current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $174.16MFor the next quarter, 6 analysts are estimating revenue of $192.34M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $182.5M.
A total of 6 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $710M, while the lowest revenue estimate was $692.2M, resulting in an average revenue estimate of $703M. In the same quarter a year ago, actual revenue was $661.82MBased on 6 analysts’ estimates, the company’s revenue will be $867.27M in the next fiscal year. The high estimate is $902.5M and the low estimate is $824.1M.
